Axicabtagene Ciloleucel

Second-line therapy with axicabtagene ciloleucel conferred a fourfold increase in EFS compared with standard-of-care treatment for diffuse large B-cell lymphoma, according to results of a randomized phase 3 study.

Kite Pharma submitted a supplemental biologics license application to the FDA that seeks expanded approval of axicabtagene ciloleucel.

Patients with diffuse large B-cell lymphoma who achieved a durable response to axicabtagene ciloleucel showed evidence of lower circulating tumor DNA levels before and after treatment, according to results of a prospective study.

Patients with relapsed or refractory large B-cell lymphoma who received second-line axicabtagene ciloleucel achieved significantly longer EFS than those who received standard of care, according to data released by the agent’s manufacturer.

A combination of lenzilumab and axicabtagene ciloleucel induced an 83% overall response rate among patients with advanced diffuse large B-cell lymphoma, according to topline data released by the agent’s manufacturer.

Product attributes appeared associated with more potent and durable responses to axicabtagene ciloleucel among patients with follicular lymphoma, according to an analysis of the ZUMA-5 trial.

Immune dysregulation resulting from high tumor burden appeared associated with poor chimeric antigen receptor T-cell expansion and resistance among patients with diffuse large B-cell lymphoma, according to study results published in Blood.

The FDA granted accelerated approval to axicabtagene ciloleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release from the agent’s manufacturer.

Last week, the FDA approved margetuximab-cmkb for the treatment of patients with metastatic HER2-positive breast cancer. It was the top story in hematology/oncology.

First-line therapy with axicabtagene ciloleucel induced an objective response in 85% of patients with high-risk large B-cell lymphoma, according to phase 2 study results presented at the virtual ASH Annual Meeting and Exposition.